Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma

Trial Profile

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Paclitaxel (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 08 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2019.
    • 08 May 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
    • 27 Apr 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top